	US 11,860,162 B2
	Marker sequences for diagnosing and stratifying SLE patients
Angelika Luking, Bochum (DE); Peter Schulz-Knappe, Hemmingen (DE); Carmen Theek, Herdecke (DE); Petra Budde, Dortmund (DE); and Anna Telaar, Dortmund (DE)
Assigned to Oncimmune Germany GmbH, Dortmund (DE)
Filed by Oncimmune Germany GmbH, Dortmund (DE)
Filed on Jul. 6, 2020, as Appl. No. 16/920,949.
Application 16/920,949 is a continuation of application No. 15/117,508, granted, now 10,746,735, previously published as PCT/EP2015/052805, filed on Feb. 10, 2015.
Claims priority of application No. 14154557 (EP), filed on Feb. 10, 2014; and application No. 14178090 (EP), filed on Jul. 22, 2014.
Prior Publication US 2021/0055296 A1, Feb. 25, 2021
Int. Cl. G01N 33/564 (2006.01)

CPC G01N 33/564 (2013.01) [G01N 2500/04 (2013.01); G01N 2800/104 (2013.01); G01N 2800/52 (2013.01)]

9 Claims

1. A method for detection, diagnosis, differential diagnosis, prognosis, therapy control, or aftercare of systemic lupus erythematosus (SLE), comprising:

a) contacting a panel of markers comprising at least one sequence selected from SEQ ID NO: HNRNPA1 (SEQ ID NO: 1063), MVP (SEQ ID NO: 1065), TMPO (SEQ ID NO: 1076), and ZNF574 (SEQ ID NO: 1082) with a bodily fluid or a tissue sample from an individual to be tested for SLE compared to a healthy control;

b) detecting an interaction of the bodily fluid or tissue sample with at least one of the marker from step a);

c) comparing a relative change of the interaction between the individual and the healthy control; and

d) identifying a SLE patient for stratification and administering at least one therapeutic agent to the SLE patient for treatment.